All PlansAdministrativeMedium impact
Voluntary nationwide recall: Potassium (Glenmark – June)
UPMC Health Plan·Pharmacy
Effective date
Jun 24, 2024
We identified it
Jun 20, 2026
Summary
Glenmark Pharmaceuticals has issued a voluntary recall of 114 batches of Potassium Chloride Extended-Release Capsules (750 mg) due to dissolution failure that could cause dangerous high potassium levels and cardiac arrest. Healthcare providers should consult with patients taking this medication and verify if their specific batches are affected through the FDA website or by calling the recall hotline.
Action Required
Immediately: Clinical staff should identify all patients prescribed Potassium Chloride Extended-Release Capsules 750 mg and contact them to verify if their medication batch is affected by the recall. Providers must consult with affected patients before discontinuing use and document any medication changes in patient records. Contact Inmar Rx Solutions at 1-877-883-9273 or check FDA website for batch verification.